GlassScriptPhysician profile
Holly M Mansur
NPI 1982113874
$4,085.97
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,134 · 2022: $1,125 · 2023: $1,538 · 2024: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,826.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,033.13 | 2021-2024 | |
| Novo Nordisk INC | $737.18 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $503.30 | 2021-2024 | Farxiga, Breztri |
| Lilly USA, LLC | $407.17 | 2021-2024 | Mounjaro, Trulicity, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.88 | 2021-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $145.13 | 2021-2023 | Belsomra, Verquvo, Steglatro |
| Glaxosmithkline, LLC. | $124.47 | 2021-2023 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $115.40 | 2022-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $100.49 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $99.10 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $88.83 | 2021-2023 | |
| Arbor Pharmaceuticals, INC. | $80.19 | 2021 | |
| Janssen Pharmaceuticals, INC | $78.32 | 2021-2023 | Xarelto |
| Pfizer INC. | $58.88 | 2023 | |
| Nestle Healthcare Nutrition INC. | $46.09 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.95 | 2021 | |
| Amarin Pharma, INC. | $30.66 | 2021 | |
| Upsher-Smith Laboratories LLC | $25.85 | 2021 | |
| Exact Sciences Corporation | $25.63 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $20.83 | 2023 | Freestyle Libre |
| Dexcom, INC. | $13.26 | 2022 | |
| Amgen INC. | $12.73 | 2022 | |
| Sumitomo Pharma America, INC. | $10.50 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Mansur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.